Core Insights - Ionis Pharmaceuticals will host a live webcast on February 25, 2026, to discuss its fourth quarter and full year 2025 financial results and key program progress [1] - The company has a strong pipeline in neurology, cardiometabolic diseases, and other high-need areas, emphasizing its leadership in RNA-targeted medicines and gene editing [1] - Ionis achieved significant milestones in 2025, including two independent product launches and anticipates continued momentum and value creation in 2026 [1] Financial Results Webcast - The webcast is scheduled for February 25, 2026, at 11:30 a.m. Eastern Time [1] - A replay of the webcast will be available for a limited time [1] Company Achievements - Ionis has successfully executed its first two independent launches in 2025, marking a defining year for the company [1] - The company will provide a business update at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 [1] Product Approvals and Collaborations - The European Commission approved DAWNZERA™ (donidalorsen) for the prevention of hereditary angioedema in adults and adolescents aged 12 years and older [1] - Partner GSK announced positive topline results from Phase 3 studies for bepirovirsen, an investigational treatment for chronic hepatitis B, involving over 1,800 patients across 29 countries [1]

Core Viewpoint - Ionis Pharmaceuticals and Otsuka Pharmaceutical have received a positive opinion from the CHMP of the European Medicines Agency for DAWNZERA (donidalorsen) aimed at preventing recurrent attacks of hereditary angioedema in adults and adolescents aged 12 years and older [1] Company Summary - Ionis Pharmaceuticals, Inc. is collaborating with Otsuka Pharmaceutical Co., Ltd. on the development of DAWNZERA [1] - The positive opinion from the CHMP is a significant step towards potential approval by the European Commission [1] Industry Summary - The decision by the CHMP highlights the ongoing advancements in treatments for hereditary angioedema, a rare but serious condition [1] - The approval process by the European Commission will be closely monitored as it may impact market dynamics for treatments targeting hereditary angioedema [1]